Gemini: Yes, Lonza Group AG is deeply and historically Swiss.
It was founded back in 1897 in Gampel, in the Swiss canton of Valais, originally taking its name from the Lonza river that flows out of the Lötschental. Today, its corporate headquarters are located in Basel, and it maintains massive operational and manufacturing footprints within Switzerland—most notably its sprawling production and development hub in Visp, alongside sites like Stein.
From a market and financial perspective, it is a heavyweight blue-chip component of the Swiss stock market, listed on the SIX Swiss Exchange and featuring prominently on the Swiss Market Index (SMI). While it has grown into a global contract development and manufacturing organization (CDMO) serving the worldwide pharma and biotech sectors, its identity, governance, and core infrastructure remain anchored tightly to Switzerland.
Reint Jelger: Does Lonza Group AG do good things for Switzerland, and the World?
Google Gemini: Lonza plays a massive role in both the Swiss economy and the global healthcare landscape, though like any major industrial and chemical giant, its impact is viewed through a few different lenses.
What Lonza does for Switzerland
- Economic Anchor & Employment: Lonza is one of Switzerland’s premier industrial employers. Its massive site in Visp (Valais) has transformed the region into a high-tech biotechnology cluster, creating thousands of specialized engineering, scientific, and manufacturing jobs.
- Tax Base & Market Weight: As a multi-billion-franc anchor of the Swiss Market Index (SMI), it contributes heavily to corporate tax revenues in its home cantons and represents a major pillar of Switzerland’s export-driven, high-value manufacturing economy.
- National Prestige in Science: It helps maintain Switzerland’s reputation as a global hub for chemical and pharmaceutical innovation—carrying forward a tradition that dates back to the 19th century.
What Lonza does for the World
- Scaling Life-Saving Medicines: As a Contract Development and Manufacturing Organization (CDMO), Lonza doesn’t just sell its own drugs; it builds and operates the complex infrastructure required to manufacture breakthrough treatments invented by biotech and pharma pioneers.
- Global Health Infrastructure: During major public health demands—such as producing ingredients and viral vector components for global vaccine rollouts or manufacturing antibody-drug conjugates (ADCs) used in advanced cancer treatments—Lonza’s massive facilities act as a backbone for worldwide medical supply chains.
- Environmental Standards: The company has faced pressure historically due to its roots in heavy chemical production, but modern corporate mandates have pushed it toward strict science-based sustainability targets, aiming for major cuts in greenhouse gas intensity and waste.
Ultimately, while it operates for profit as a multinational enterprise, its daily output directly dictates whether complex, life-saving therapies can actually be manufactured at a scale that serves patients globally.
Reint Jelger: 659,60 CHF is their current share price I see
Gemini: Spot on—Lonza (LONN) traded right around 659.60 CHF on the SIX Swiss Exchange today.
That puts its total market capitalization at approximately 46.3 billion CHF, reflecting the major rally it has had over the past year (up over 20% from its 52-week lows down around 454 CHF).
At that valuation, it trades at a forward P/E multiple around 31x to 40x earnings with a modest dividend yield (~0.75%–0.80%), as investors price in its high-margin growth from biologics and antibody-drug conjugate (ADC) drug manufacturing.